MX2022011131A - Nuevo uso y metodo de tratamiento. - Google Patents

Nuevo uso y metodo de tratamiento.

Info

Publication number
MX2022011131A
MX2022011131A MX2022011131A MX2022011131A MX2022011131A MX 2022011131 A MX2022011131 A MX 2022011131A MX 2022011131 A MX2022011131 A MX 2022011131A MX 2022011131 A MX2022011131 A MX 2022011131A MX 2022011131 A MX2022011131 A MX 2022011131A
Authority
MX
Mexico
Prior art keywords
treatment
new use
pharmaceutical composition
administration
active ingredient
Prior art date
Application number
MX2022011131A
Other languages
English (en)
Inventor
Martin Vidaeus
Hans Ageland
Ulf Björklund
Gerhard Garhöfer
Original Assignee
Redwood Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redwood Pharma Ab filed Critical Redwood Pharma Ab
Publication of MX2022011131A publication Critical patent/MX2022011131A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona una composición farmacéutica que comprende como principio activo un hidrogel inversamente termorreversible, para la administración en el ojo de sujetos mamíferos. En particular, se refiere a una composición farmacéutica para su uso en, y a un método para, el tratamiento oftálmico de la enfermedad del ojo seco.
MX2022011131A 2020-03-12 2021-03-12 Nuevo uso y metodo de tratamiento. MX2022011131A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20162821 2020-03-12
PCT/EP2021/056314 WO2021180913A1 (en) 2020-03-12 2021-03-12 New use and method of treatment

Publications (1)

Publication Number Publication Date
MX2022011131A true MX2022011131A (es) 2022-11-14

Family

ID=69810711

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011131A MX2022011131A (es) 2020-03-12 2021-03-12 Nuevo uso y metodo de tratamiento.

Country Status (12)

Country Link
US (1) US20230131227A1 (es)
EP (1) EP4117622A1 (es)
JP (1) JP2023517317A (es)
KR (1) KR20220152244A (es)
CN (1) CN115297839A (es)
AU (1) AU2021233161A1 (es)
BR (1) BR112022018060A2 (es)
CA (1) CA3170370A1 (es)
IL (1) IL296120A (es)
MX (1) MX2022011131A (es)
TW (1) TW202200208A (es)
WO (1) WO2021180913A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
LT2689774T (lt) 2011-03-21 2019-03-25 Broda Technologies Co., Ltd Atvirkščiai termiškai grįžtama hidrogelio kompozicija
US20170112936A1 (en) * 2014-05-23 2017-04-27 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
US20180098937A1 (en) * 2016-10-12 2018-04-12 Ps Therapies Ltd Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
CN108295318B (zh) * 2018-01-31 2021-07-06 西安泰科迈医药科技股份有限公司 一种温敏可注射型泪道栓及其制备方法

Also Published As

Publication number Publication date
CN115297839A (zh) 2022-11-04
BR112022018060A2 (pt) 2022-10-25
EP4117622A1 (en) 2023-01-18
KR20220152244A (ko) 2022-11-15
WO2021180913A1 (en) 2021-09-16
IL296120A (en) 2022-11-01
US20230131227A1 (en) 2023-04-27
JP2023517317A (ja) 2023-04-25
TW202200208A (zh) 2022-01-01
CA3170370A1 (en) 2021-09-16
AU2021233161A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
WO2011053801A3 (en) Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye
WO2016042163A3 (en) Ophthalmic drug compositions
JP2019532931A (ja) 眼瞼炎の治療に使用するための医薬組成物
BRPI0608152A2 (pt) formulações para tratamento ocular
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2013011314A (es) Tratamientos oftalmicos.
RU2017129247A (ru) Способы и композиции для лечения болезни сухого глаза и других глазных заболеваний
MX2011008616A (es) Peptidos utiles en el tratamiento y/o cuidado de la piel , mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
ATE428401T1 (de) Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten
MX2020005217A (es) Composicion oftalmica y dispositivo de administracion de la misma.
RU2018114926A (ru) Композиции гиалуроновой кислоты с высокоэластичными свойствами и способы их применения
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
ATE529417T1 (de) 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält
MX355770B (es) Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico.
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
Bennett et al. Material, immunological, and practical perspectives on eye drop formulation
WO2016060917A3 (en) Formulations for histatin therapeutics
BR112014009761B8 (pt) Composição de reticulação melhorada entregue por iontoforese, útil para o tratamento de ceratocone
AR092842A1 (es) Tratamiento de enfermedades inflamatorias oculares usando laquinimod
MX2023009352A (es) Metodos para la administracion oftalmica de roflumilast.
MX2022011131A (es) Nuevo uso y metodo de tratamiento.
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.